SCHEMBL2415345

SCHEMBL2415345

Clc1ccc(-c2nc3ccccc3[nH]2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 1.00
RAB9A P51151 11/20 1.00
KDM4E B2RXH2 10/20 1.00
ALDH1A1 P00352 8/20 1.00
PKM P14618 4/20 0.68
GAA P10253 1/20 0.59
EPHX2 P34913 2/20 0.58
LDHA P00338 1/20 0.58
SMN1; SMN2 Q16637 7/20 0.57
HSD17B10 Q99714 3/20 0.57
HPGD P15428 3/20 0.57
TP53 P04637 2/20 0.57
MAPT P10636 2/20 0.57
POLB P06746 2/20 0.57
GFER P55789 1/20 0.57
ABCB11 O95342 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
PKN1 Q16512 1/20 0.54
PKN2 Q16513 1/20 0.54
GPR55 Q9Y2T6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14969277 0.83 NPC1 (0.71) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL14969101 0.82 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL19064366 0.82 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL29855452 0.82 NPC1 (0.69) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL17624580 0.81 ALDH1A1 (0.70) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL371179 0.81 NPC1 (0.78) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL3335441 0.81 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL10695095 0.81 NPC1 (0.68) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL12402878 0.81 NPC1 (0.68) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL3054720 0.81 NPC1 (0.68) NPC1RAB9AKDM4EALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
EP-1807085-B1 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors XENON PHARMACEUTICALS INC (CA) 2013-08-21 EP disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-8198307-B2 Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-06-12 US disclosed
US-8026255-B2 Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists HOFFMAN-LA ROCHE INC. (US) 2011-09-27 US disclosed
EP-2266569-A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
EP-2266569-A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20100222350-A1 PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES BINGGELI ALFRED 2010-09-02 US disclosed
US-7767677-B2 Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2010-08-03 US disclosed
US-7754744-B2 Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists HOFFMANN-LA ROCHE INC. (US) 2010-07-13 US disclosed
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-10 US disclosed
US-20080096895-A1 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors XENON PHARMACEUTICALS INC. (CA) 2008-04-24 US disclosed
US-20080096895-A1 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors XENON PHARMACEUTICALS INC. (CA) 2008-04-24 US disclosed
US-20080096895-A1 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors XENON PHARMACEUTICALS INC. (CA) 2008-04-24 US disclosed
US-20080045544-A1 Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 US disclosed
CN-101083994-A Heterocyclic derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2007-12-05 CN disclosed
EP-1807085-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-07-18 EP disclosed
WO-2006034440-A2 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222350-A1 PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES SSTR5, SSTR3, SSTR1 NPC1 1205/4885RAB9A 2541/4885KDM4E 4109/4885
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF P2RX5, P2RX3, ABCG2 NPC1 350/4885RAB9A 2252/4885KDM4E 2840/4885
US-20080096895-A1 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors SCD, SCD5, ECHS1 NPC1 309/4885RAB9A 1163/4885KDM4E 376/4885
US-20080045544-A1 Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives SSTR5, SSTR3, SSTR1 NPC1 1205/4885RAB9A 2541/4885KDM4E 4109/4885
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME TYR, MCHR1, MCHR2 NPC1 223/4885RAB9A 687/4885KDM4E 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.